http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-781524-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05a203d85ee01909eaf728dc16f0f6cb |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-65 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-65 |
| filingDate | 1955-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1957-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-781524-A |
| titleOfInvention | Improvements in or relating to therapeutic compositions for the treatment of mastitis |
| abstract | A composition effective against mastitis comprises calcium dioxytetracycline in an aqueous vehicle containing a non-toxic alkaline earth metal (including magnesium) alginate as a thickening agent and a pharmaceutically acceptable suspending agent. The alginate thickening agent may be prepared in situ by reacting sodium alginate with alkaline earth metal salts of hydroxy carboxylic acids of low molecular weight and low toxicity such as calcium lactate, magnesium lactate and calcium tartrate. Specified suspending agents include polyoxymethylene derivatives of fatty acid esters of anhydro sugar alcohols such as sorbitan. Stabilizing agents such as sodium bisulphite and sodium formaldehyde sulphoxylate and germicides such as parahydroxybenzoic acid esters, phenol and benzyl alcohol may also be present. The compositions may also include polymyxin in minor proportion. The preparation is preferably prepared by forming an aqueous suspension of the alginate thickening agent, adding the suspending agent and stabilizers, and homogenizing. A small quantity of this is added the antibiotic or antibiotics, and the germicides, and the remainder gradually stirred in and the preparation again homogenized. In an example, a preparation comprising calcium lactate, sodium alginate, a suspending agent, sodium bisulphite, calcium dioxytetracycline, polymyxin B sulphate, methyl p-hydroxy benzoate and propyl p-hydroxy benzoate is described. Specification 732,751 is referred to. |
| priorityDate | 1954-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 40.